Search

Displaying results 2601 - 2610 of 3733 in total
  1. Drug

    Eravacycline

    go.drugbank.com/drugs/DB12329
    ApprovedInvestigational

    Eravacycline, known as Xerava by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive aerobic, and facultative bacte...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  2. Drug

    Lynestrenol

    go.drugbank.com/drugs/DB12474
    ApprovedWithdrawn

    Lynestrenol is a progestin and prodrug of norethisterone.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  3. Drug

    Copanlisib

    go.drugbank.com/drugs/DB12483
    ApprovedInvestigational

    Copanlisib is a selective pan-Class I phosphoinositide 3-kinase (PI3K) inhibitor with preferential activity against the alpha and delta isoforms. PI3K, a lipid kinase that activates downstream signalling pathways involved in cell surviva...

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  4. Drug

    1,2-Benzodiazepine

    go.drugbank.com/drugs/DB12537
    ApprovedInvestigationalWithdrawn

    Benzodiazepine is under investigation for the prevention of Delirium and C.Surgical Procedure; Cardiac. Benzodiazepine has been investigated for the treatment of Obesity, Sleep Apnea, Obstructive, and Disorders of Gallbladder, Biliary Tr...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  5. Drug

    Samidorphan

    go.drugbank.com/drugs/DB12543
    ApprovedInvestigational

    [A235638, A235643] Samidorphan is a novel opioid antagonist structurally related to [naltrexone], with a higher affinity for opioid receptors, more potent μ-opioid receptor antagonism, higher oral bioavailability

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  6. Drug

    Piperine

    go.drugbank.com/drugs/DB12582
    Investigational

    Bioperine has been used in trials studying the treatment of Multiple Myeloma and Deglutition Disorders.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP3A Inhibitors
  7. Drug

    Lurbinectedin

    go.drugbank.com/drugs/DB12674
    ApprovedInvestigational

    Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma, chronic lymphocytic leukemia (CLL), breast cancer, and small-cell lung cancer (SCLC). It is a derivative...

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  8. Drug

    Ritanserin

    go.drugbank.com/drugs/DB12693
    Investigational

    Ritanserin has been used in trials studying the treatment of Cocaine-Related Disorders.

    Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  9. Drug

    Setileuton

    go.drugbank.com/drugs/DB19550
    Investigational

    Setileuton is a small molecule drug. The usage of the INN stem '-leuton' in the name indicates that Setileuton is a 5-lipo-oxygenase inhibitor, anti-inflammatory. Setileuton is under investigation in clinical trial NCT00404313 (The Effec...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  10. Drug

    Mifentidine

    go.drugbank.com/drugs/DB19721
    Experimental

    The usage of the INN stem '-tidine' in the name indicates that Mifentidine is a histamine- H2​-receptor antagonist, cimetidine derivative. Mifentidine has a monoisotopic molecular weight of 228.14 Da.

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme Inhibitors